Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kineta Inc.

Latest From Kineta Inc.

Video: KPI Therapeutics Chief Explains Company's Virtual Business Model

Charles Magness details KPI's clinical ambitions to develop potential first-is-class autoimmune and chronic pain treatments, in an interview at Biotech Showcase.

BioPharmaceutical Business Strategies

Recent Tech Transfer Deals, March 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Tech Transfers column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors.

BioPharmaceutical Medical Device

Natural Products: Back In Vogue?

Several small biotechs are heading back to nature, spotting promising drug targets in exotic plants, sea creatures, and venomous animals, even as Big Pharma and venture capital remain skeptical of the approach.

Kineta Inc.

Kineta Inc. is working an array of novel Kv1.3 potassium channel blockers derived from the venom of the Caribbean sea anemone. They are designed to suppress activation of effector memory T-cells, which are mediators of inflammation and tissue damage in multiple sclerosis, rheumatoid arthritis, type 1 diabetes mellitus and other autoimmune diseases. Kineta's studies indicate that the company's lead compound appears to inhibit only the effector memory T-cells and leave other immune functions unperturbed.
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Alias(es)
  • Kineta One LLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Kineta Inc.
  • Senior Management
  • Charles Magness, PhD, Pres. & CEO
    Shawn Iadonato, PhD, EVP, CSO
    William Cadwallader, SVP, Corp. Dev.
    Kenneth North, SVP, Fin.
  • Contact Info
  • Kineta Inc.
    Phone: (206) 378-0400
    219 Terry Ave N
    Ste. 300
    Seattle, WA 98109